文献速递骨质疏松与代谢性骨病创伤骨科

双膦酸盐药物假期对绝经后骨质疏松症临床骨折风险的影响

Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk.
PubMed 文献 · Osteoporos Int · 2017-09-05

在法国里尔大学医院开展的一项回顾性分析纳入183例绝经后骨质疏松症女性,比较一线双膦酸盐治疗3至5年后停药(药物假期)与继续治疗者的临床骨折风险,发现药物假期组新发临床骨折风险高40%(HR 1.40,95%CI 1.12-1.60,p=0.0095)。

要点

  • 一线双膦酸盐治疗3至5年后停药即药物假期,与继续治疗相比新发临床骨折风险高40%。
  • 药物假期组随访期间新发临床骨折发生率为16.1%(5/31),继续治疗组为11.9%(16/135)。
  • 研究为里尔大学医院的回顾性分析,随访6至36个月,平均31.8个月(SD 8.2)。

核心结论

  • 绝经后骨质疏松症女性在一线双膦酸盐治疗3至5年后,采取药物假期者新发临床骨折风险比继续治疗者高40%。

研究设计与样本

  • 在里尔大学医院开展的回顾性分析,纳入183例曾接受一线双膦酸盐治疗3至5年的绝经后骨质疏松症女性。
  • 患者曾用阿仑膦酸钠(n=81)、利塞膦酸钠(n=73)、唑来膦酸(n=20)和伊班膦酸钠(n=9)。
  • 166例纳入随访分析,其中药物假期组31例、继续治疗组135例,随访6至36个月(平均31.8个月,SD 8.2)。

主要发现

  • 183例患者平均年龄61.8岁(SD 8.7)。
  • 药物假期组新发临床骨折发生率为16.1%(5/31),继续治疗组为11.9%(16/135)。
  • 充分校正后,药物假期组新发临床骨折的风险比为1.40(95%CI 1.12-1.60;p=0.0095)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: A cohort of 183 postmenopausal women, who had either discontinued or continued bisphosphonates (BPs) after first-line therapy, was used to investigate the relationships between "drug holiday" and clinical fracture. The risk of new clinical fractures was found to be 40% higher in women who had taken a BP "drug holiday." INTRODUCTION: BPs are the most widely used treatment for postmenopausal osteoporosis. The optimal treatment duration, however, remains unclear. The purpose of this study was to evaluate the fracture risk in postmenopausal women with osteoporosis after discontinuing BP treatment (BP "drug holiday"). METHODS: A retrospective analysis was performed at Lille University Hospital (LUH) on postmenopausal women with osteoporosis who had taken a "drug holiday" or continued treatment after first-line BP therapy (3 to 5 years). The occurrence of new clinical fractures during follow-up was also explored. Cox proportional hazards models were used to investigate the relationships between BP "drug holiday" and the occurrence of clinical fractures, while controlling for confounding factors. Survival without new clinical fractures was analyzed using Kaplan-Meier curves and log-rank tests. RESULTS: One hundred eighty-three women (mean age: 61.8 years; SD: 8.7) who had previously undergone BP treatment for 3 to 5 years were enrolled in our study. The patients had received alendronate (n = 81), risedronate (n = 73), zoledronic acid (n = 20), and ibandronate (n = 9). In 166 patients ("drug holiday" group: n = 31; continuous-treatment group: n = 135), follow-up ranged from 6 to 36 months (mean duration: 31.8 months; SD: 8.2). The incidences of new clinical fractures during follow-up were 16.1% (5/31) and 11.9% (16/135). After full adjustment, the hazard ratio of new clinical fractures among "drug holiday" patients was 1.40 (95% CI: 1.12-1.60; p = 0.0095). CONCLUSIONS: After first-line BP therapy in postmenopausal women with osteoporosis, the risk of new clinical fractures was 40% higher in subjects who took a bisphosphonate drug holiday.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Mignot MA, Taisne N, Legroux I, et al. Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk. Osteoporos Int. 2017. PMID: 28875236. doi:10.1007/s00198-017-4215-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。